Effects of sodium-glucose co-transporter 2 inhibition with empagliflozin on potassium handling in patients with acute heart failure

Eur J Heart Fail. 2021 Jun;23(6):1049-1052. doi: 10.1002/ejhf.2197. Epub 2021 May 11.

Authors

Joost C Beusekamp¹, Jasper Tromp^{1

2

3}, Eva M Boorsma¹, Hiddo J L Heerspink^{1

4}, Kevin Damman¹, Adriaan A Voors¹, Peter van der Meer¹

Affiliations

¹ University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.
² National Heart Centre Singapore & Duke-National University of Singapore, Singapore.
³ Saw Swee Hock School of Public Health, National University of Singapore, Singapore.
⁴ George Institute for Global Health, Sydney, Australia.

No abstract available

Publication types

Letter

MeSH terms

Benzhydryl Compounds
Diabetes Mellitus, Type 2* / drug therapy
Glucose
Glucosides
Heart Failure* / drug therapy
Humans
Potassium
Sodium
Sodium-Glucose Transporter 2
Sodium-Glucose Transporter 2 Inhibitors / therapeutic use*

Substances

Benzhydryl Compounds
Glucosides
SLC5A2 protein, human
Sodium-Glucose Transporter 2
Sodium-Glucose Transporter 2 Inhibitors
Sodium
empagliflozin
Glucose
Potassium